What is the pathognomonic fracture of neurobrucellosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 22, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Pathognomonic Feature of Neurobrucellosis

The pathognomonic feature of neurobrucellosis is vertebral body collapse, particularly affecting the lumbar spine, with L4 being commonly involved. 1

Clinical Presentation and Diagnosis

Neurobrucellosis is a serious complication of brucellosis, a zoonotic infection caused by bacteria of the genus Brucella. When it affects the spine, it can lead to:

  • Vertebral body collapse (pathognomonic finding)
  • Meningitis or meningoencephalitis
  • Radiculopathy with sensory and motor deficits
  • Back pain with possible radicular symptoms

Diagnostic Criteria

The diagnosis of neurobrucellosis requires:

  1. Clinical signs and symptoms suggestive of neurobrucellosis
  2. Positive serology for Brucella (titers ≥1:160 in endemic areas)
  3. Cerebrospinal fluid (CSF) abnormalities:
    • Lymphocytosis
    • High protein levels
    • Low glucose levels
    • Positive Brucella antibodies in CSF

Laboratory Testing

  • Blood cultures (sensitivity 15-70%)
  • Brucella tube agglutination test (Wright test) with titers ≥1:160 in endemic areas 2
  • In non-endemic areas, ELISA screening followed by confirmatory agglutination test 3

Imaging

MRI is the preferred imaging modality for neurobrucellosis affecting the spine, showing:

  • Vertebral body collapse (pathognomonic)
  • Disc space involvement
  • Possible epidural abscess formation

Treatment Approach

Antimicrobial Therapy

For neurobrucellosis, the recommended regimen includes:

  1. First-line regimen: Doxycycline 100 mg twice daily for 3-6 months plus rifampicin 600-900 mg daily for 3-6 months, with streptomycin 15 mg/kg daily intramuscularly for the first 2-3 weeks 2

  2. Alternative regimen: Doxycycline plus rifampicin with ceftriaxone instead of streptomycin (preferred for neurobrucellosis due to better CSF penetration) 4

Duration of Treatment

  • Treatment should continue for 3-6 months for neurobrucellosis with vertebral involvement 2
  • Monitoring of clinical response and serological titers is essential

Surgical Management

Surgical intervention is indicated in cases of:

  • Spinal cord compression
  • Significant vertebral collapse causing instability
  • Abscess formation requiring drainage
  • Failure of medical treatment 2

The typical surgical approach involves:

  • Neural tissue decompression
  • Posterior short segment transpedicular screw fixation and stabilization 1

Follow-Up and Prognosis

  • Regular clinical and serological follow-up for at least 2 years after treatment 2
  • Monitor for relapse, particularly in patients treated with regimens other than doxycycline-streptomycin
  • Long-term sequelae may include limitation of movement and chronic pain

Prevention

  • Pasteurization of dairy products
  • Vaccination of livestock
  • Use of personal protective equipment when handling potentially infected animals
  • Public education about risks of consuming unpasteurized dairy products

Important Considerations

  • In endemic areas, image-guided aspiration biopsy may not be necessary if blood cultures are positive for Brucella or if serology is strongly positive 3
  • In non-endemic areas, evaluation by an infectious disease specialist and a spine surgeon is recommended 3
  • Streptomycin use may be limited by its poor CSF penetration and potential neurotoxicity 4

Remember that early diagnosis and appropriate treatment are crucial to prevent permanent neurological complications from vertebral collapse in neurobrucellosis.

References

Research

Collapsed L4 vertebral body caused by brucellosis.

Journal of Korean Neurosurgical Society, 2014

Guideline

Brucellosis Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Treatment of neurobrucellosis: what is known and what remains to be answered.

Expert review of anti-infective therapy, 2007

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.